“Long Covid” linked to disease of small airways in lungs

Researchers report that persistent disease of the small airways in the lungs, with yet unknown long-term effects, appears to be a possible log-term effect of COVID-19, and it is unrelated to initial infection severity. The findings were published on March 15, 2022 in Radiology. “For the first time, we’re describing small airways disease in this population of COVID-19 patients with […]

Home-based flu tests as accurate as rapid diagnostic testing in clinical settings

Home-based, self-administered tests for influenza are comparable in accuracy to rapid diagnostic tests in clinical settings, according to a recently published, peer-reviewed study. “Home tests are a valuable tool to support the management of influenza and other respiratory infections,” said Matthew J. Thompson, professor of global health and family medicine at the University of Washington School of Medicine in Seattle. Thompson is the senior […]

Sleep apnea accelerates aging, but treatment may reverse it

Obstructive sleep apnea (OSA) affects 22 million people in the U.S. and is linked to a higher risk of hypertension, heart attacks, stroke, diabetes and many other chronic conditions. But now researchers from the University of Missouri School of Medicine have found that untreated OSA also accelerates the biological aging process and that appropriate treatment can slow or possibly reverse the trend. […]

Standard for pulmonary function tests gets an update

In the latest update to the pulmonary function tests technical standard series, the American Thoracic Society and European Respiratory Society address the uncertainty around the interpretation of the tests which are essential in determining the extent of respiratory dysfunction. The update was recently published in the European Respiratory Journal ahead of a planned webinar series by the ATS. The update builds upon prior recommendations from the American […]

FDA grants Tentative Approval for Yutrepia to treat pulmonary arterial hypertension – Liquidia Corpn

Liquidia Corporation has announced that the FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder, previously referred to as LIQ 861. Yutrepia is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that Yutrepia has met all regulatory standards for […]

Can a dangerous microbe offer a new way to silence pain?

Deadly anthrax toxin blocks multiple types of pain in mice, study shows. Anthrax has a scary reputation. Widely known to cause serious lung infections in humans and unsightly, albeit painless, skin lesions in livestock and people, the anthrax bacterium has even been used as a weapon of terror. Now the findings of a new study suggest the dreaded microbe also […]

FDA approves Dupixent as add-on treatment for moderate-to-severe asthma – Sanofi + Regeneron

The FDA has approved Dupixent (dupilumab), from Sanofi + Regeneron, as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. The FDA approval is based on data from a Phase III randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of Dupixent combined with […]

European Commission approves Ronapreve to treat of non-hospitalized patients (outpatients) with confirmed COVID-19 who do not require oxygen supplementation

Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other countries. The EC granted marketing authorization for the antibody cocktail for people aged 12 years and older for the treatment of non-hospitalized patients (outpatients) with confirmed COVID-19 who […]

Cystic fibrosis faithfully modelled in a human Lung Airway Chip

First microfluidic organ-on-a-chip model of the disease could help bring much needed drugs, and personalized medicine approaches to patients. The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In individuals carrying mutations in the cystic fibrosis transmembrane conductance regulator […]